4971 results for "Psychedelics"
Effects of External Stimulation on Psychedelic State Neurodynamics.
ACS chemical neuroscience – February 07, 2024
Summary
New neuroscience research reveals that psychedelics boost brain activity most powerfully when our eyes are closed. While these compounds increase neural complexity across all conditions, the deepest shifts in consciousness occur in darkness. Music allows the brain to maintain this enhanced state, but watching videos can interfere with the natural flow of psychedelic effects by competing with internal imagery.
Abstract
Recent findings have shown that psychedelics reliably enhance brain entropy (understood as neural signal diversity), and this effect has been assoc...
Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use.
PNAS nexus – April 01, 2025
Summary
Psychedelics may actually reduce delusional thinking patterns, according to recent findings. While 30% of users reported minor visual disturbances (HPPD-like effects), less than 1% found these changes distressing. Young women and those with prior psychiatric diagnoses were more likely to experience these adverse effects. Notably, psychedelic use was linked to decreased delusional ideation, challenging concerns about magical thinking.
Abstract
Interest in using psychedelic drugs to treat psychiatric disorders is growing rapidly. While modern controlled clinical trials show a favorable saf...
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review
Frontiers in Psychiatry – June 26, 2023
Summary
Ketamine and hallucinogens like Psilocybin significantly enhance brain cell connections, particularly under stress. A comprehensive review of 84 studies (71 on Ketamine, 9 on psychedelics) found Ketamine counteracted stress-related reductions in Hippocampus synaptic markers. Psychedelics generally increased markers like Synapsin I, demonstrating Synaptic plasticity. This Neuroscience insight offers compelling potential for Medicine and Clinical psychology, including Psychiatry and the Treatment of Major Depression, underscoring the therapeutic value in Psychedelics and Drug Studies.
Abstract
Background Ketamine and psychedelics have abuse liability. They can also induce “transformative experiences” where individuals experience enhanced ...
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
Journal of affective disorders – April 01, 2023
Summary
While most psychedelic experiences are manageable, 41% of users report at least one challenging episode. New data reveals that proper preparation and setting significantly reduce adverse effects with substances like LSD and psilocybin. Mental state, environment, and support are key factors affecting risk. Only 2.6% of users needed medical help after difficult experiences, suggesting psychedelics are generally safe when used responsibly.
Abstract
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence...
[Neurotrophic mechanisms of psychedelic therapy].
Biologie aujourd'hui – January 01, 2019
Summary
Therapeutic effects of psychedelics can last long after the drug is gone, suggesting they trigger lasting brain changes. Studies reveal how compounds like LSD and ketamine (kétamine) impact neurotrophic factors such as BDNF. The central idea is that despite different receptor targets, these psychedelics initiate similar beneficial plastic adaptations in the brain's prefrontal cortex. Positive findings indicate these mechanisms could effectively treat conditions like depression (dépression) and addiction, offering new avenues for mental health care.
Abstract
Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and beh...
Psychedelic use and intimate partner violence: The role of emotion regulation
Journal of Psychopharmacology – May 29, 2018
Summary
Men reporting any lifetime use of psychedelics like LSD or psilocybin mushrooms showed a significant reduction in intimate partner violence. Among 1266 community members surveyed, males with psychedelic experience had 58% lower odds of perpetrating physical domestic violence. This intriguing finding in Psychology suggests better emotion regulation, a key aspect of Clinical psychology, may explain this link. Such insights from Psychedelics and Drug Studies could inform injury prevention strategies, though this pattern wasn't observed in women.
Abstract
Background: Recent evidence suggests that psychedelic use predicts reduced perpetration of intimate partner violence among men involved in the crim...
Values and Beliefs of Psychedelic Drug Users: A Cross-Cultural Study
Journal of Psychoactive Drugs – June 01, 2006
Summary
Individuals who use hallucinogens like psilocybin demonstrate a distinct psychological profile, scoring higher on mystical beliefs, spirituality, and concern for others, while valuing financial prosperity less. This pattern emerged from a psychology study of 183 people, including 88 psychedelic users, 29 non-psychedelic illegal drug users, and 66 social drinkers, and held true across cultures. Furthermore, both groups using illegal drugs exhibited greater empathy than social drinkers. This suggests unique enduring psychological characteristics, though pre-existing traits of users may contribute to these associations with psychedelics.
Abstract
Psychedelic drugs such as LSD and psilocybin are often claimed to be capable of inducing life-changing experiences described as mystical or transce...
Restructuring consciousness –the psychedelic state in light of integrated information theory
Frontiers in Human Neuroscience – June 12, 2015
Summary
Psychedelic drugs like psilocybin dramatically alter consciousness, offering a unique window into psychology and cognitive science. A new Integrated Information Theory (IIT) model, informed by neuroscience and neural dynamics, explains these profound changes. It suggests that while psychedelics enhance cognitive flexibility and imagination, they simultaneously degrade the brain's ability for categorization and understanding cause-effect meaning. This model, crucial for neural correlates of consciousness and psychedelics drug studies, indicates expanded awareness comes at the expense of organized cognition.
Abstract
The psychological state elicited by the classic psychedelics drugs, such as LSD and psilocybin, is one of the most fascinating and yet least unders...
Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
OpenAlex – April 28, 2023
Summary
Better psychedelic preparedness predicts improved mental health outcomes. A new 20-item Psychedelic Preparedness Scale (PPS), developed using a Delphi method with experts in clinical psychology and users, measures this crucial factor. Psychometrics, including exploratory and confirmatory factor analysis, validated the scale in two samples of 516 and 716 users. It showed excellent reliability (ω = 0.954) and strong convergent and discriminant validity. Administered before a psilocybin retreat (N=46), the PPS demonstrated its utility in Applied Psychology and Psychedelics and Drug Studies, indicating how readiness impacts subsequent mental health and wellbeing.
Abstract
Preparing participants for psychedelic experiences is crucial for ensuring these experiences are safe, and potentially, beneficial. However, there ...
A lasting impact of serotonergic psychedelics on visual processing and behavior
OpenAlex – July 06, 2024
Summary
Psilocybin and other Serotonergic psychedelics can yield therapeutic effects lasting weeks, profoundly shifting perception. This Neuroscience and Psychology research, part of Psychedelics and Drug Studies, reveals how these Hallucinogens alter the Sensory system. People using 5-HT2A-agonist psychedelics showed slowed responses to a visual Stimulus and increased visual cortex involvement. Mice exhibited altered visual cortex activity, indicating a shift from top-down to bottom-up processing. This Neurotransmitter Receptor Influence on Behavior, explored via Biochemical Analysis and Sensing Techniques, persists.
Abstract
Abstract Serotonergic psychedelics (e.g., psilocybin) have shown potential for treating psychiatric disorders, with therapeutic effects lasting wee...
Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia
Psychoactives – May 25, 2023
Summary
Psychedelic experiences profoundly shift individuals' relationship with the natural world. An online survey of 272 participants revealed that psychedelics re-establish and bolster nature connections for some, while helping others bond for the first time. Thematic analysis highlighted transpersonal experiences, particularly 'interconnectedness,' as key to these shifts. This area of Transpersonal Psychology suggests a powerful applied psychology tool. Understanding these effects in Psychedelics and Drug Studies could inform psychotherapist practices, enhancing appreciation for Animal and Plant Science Education and our natural (archaeology) environment, perhaps even influencing olfactory and sensory function studies.
Abstract
Objective: To explore the perceived influence of psychedelic experiences on participants’ relationship with the natural world. Method: A total of 2...
Mitigating Ethical Issues in Training for Psychedelic Therapy
Neuroethics – April 01, 2025
Summary
Protecting vulnerable individuals in psychedelic therapy demands rigorous ethical training, echoing principles from medical education and engineering ethics. Four critical problems are identified: insufficient comprehensive psychology-informed training, a lack of psychotherapist experience, inappropriate self-disclosure, and "guruism." Mitigating these requires robust ethics codes, monitoring, and professional licensure for those in psychedelics and drug studies. Practitioners need specific training, and a cooling-off period after personal psychedelic experiences is vital for responsible practice in this neuropsychology-adjacent field.
Abstract
Abstract In the present paper, we analyze the ethical issues in training for psychedelic therapy and discuss mitigation strategies for these issues...
Nurses' Perceptions of Psychedelics to Address Mental Health Problems in the United States.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
No Summary
Abstract
To explore nurses' knowledge, attitudes, and perceived social norms about psychedelic use to address mental health conditions. Data were collected ...
The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.
Psychedelic medicine (New Rochelle, N.Y.) – September 01, 2024
Summary
No Summary
Abstract
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of ...
Psychedelic risks and benefits: A cross-sectional survey study.
Journal of psychopharmacology (Oxford, England) – May 01, 2025
Summary
No Summary
Abstract
As classic psychedelics' therapeutic potential is studied and their popularity continues to rise, it is important to establish their relative risks...
Tags
Processing of self-related thoughts in experienced users of classic psychedelics: A source localisation EEG study.
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
No Summary
Abstract
Psychedelics have gained increasing interest in scientific research due to their ability to induce profound alterations in perception, emotional pr...
Naturalistic use of psychedelics does not modulate processing of self-related stimuli (but it might modulate attentional mechanisms): An event-related potentials study.
Psychophysiology – August 01, 2024
Summary
No Summary
Abstract
Classic psychedelics are able to profoundly alter the state of consciousness and lead to acute experiences of ego dissolution - the blurring of the...
If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.
The journal of pain – October 01, 2022
Summary
No Summary
Abstract
Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of conscio...
Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
Journal of psychoactive drugs – January 01, 2023
Summary
No Summary
Abstract
There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure ...
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder.
British journal of pharmacology – October 28, 2024
Summary
No Summary
Abstract
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid-acting antidepressants (...
Intellectual Property of Psychedelics for Addiction Treatment: Enabling Access and Protecting Innovation Opportunities Through Preserving the Public Domain.
Journal of studies on alcohol and drugs – September 01, 2024
Summary
No Summary
Abstract
Recent research has shown potential for psychedelic therapeutics as addiction treatments; however, some academic institutions, commercial entities,...
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Journal of Psychopharmacology – August 26, 2022
Summary
MDMA and other serotonergic hallucinogens are generally well tolerated in Psychology and Psychiatry treatments, a review of 44 articles encompassing 598 patients reveals. Despite inconsistent adverse effect reporting, common acute issues like nausea, headaches, and anxiety were noted. Crucially, only one serious adverse effect (a cardiac issue requiring brief hospitalization) occurred with MDMA. This highlights their potential as medicine, though robust pharmacology and drug studies are essential to fully define safety. Challenging experiences may even prove therapeutically beneficial.
Abstract
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Befor...
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Journal of affective disorders – March 01, 2025
Summary
Higher doses of psilocybin create more profound psychedelic experiences, which strongly correlate with better outcomes in people with treatment-resistant depression. A single dose, combined with psychological support, showed that participants who reported deeper mystical experiences and visual effects were more likely to see significant improvements in their depression symptoms after three weeks.
Abstract
To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For tre...
Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming
Molecular Psychiatry – October 11, 2024
Summary
A single dose of the hallucinogen psilocybin dramatically reduced symptoms resembling Obsessive-Compulsive Spectrum Disorders. In a trial with 50 mice, a placebo-like vehicle increased self-grooming by 118.71% over 21 days. Psilocybin decreased it by 14.60%, and a psychedelic mushroom extract by 19.20%. Concomitant anxiety and other behaviors also improved. This impactful finding in Psychology highlights psilocybin's potential in Medicine, offering new avenues for Psychedelics and Drug Studies, including those addressing Body Image and Dysmorphia.
Abstract
Abstract Obsessive compulsive disorder (OCD) is a highly prevalent disorder that causes serious disability. Available treatments leave 40% or more ...
Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.
Current topics in behavioral neurosciences – July 31, 2024
Summary
While generally safer than many recreational substances, psychedelics like LSD and psilocybin can profoundly alter consciousness through unique interactions with brain serotonin systems. Their classification includes three main types: phenethylamines, tryptamines, and ergolines. Though showing promise in mental health treatment, these substances carry risks of anxiety, dissociation, and psychological harm, particularly when combined with other drugs or used improperly.
Abstract
Psychedelics are a group of substances within the heterogeneous class of hallucinogenic drugs. Via binding to the serotonin (5-HT) 2A receptor, psy...
Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
Addiction – June 06, 2024
Summary
The burgeoning push for psychedelic legalization, paralleling cannabis's journey, often uses poorly-evidenced therapeutic claims to establish de facto recreational markets. This observation, spanning Public administration, Business, and Political science, informs Psychedelics and Drug Studies. With four nations already permitting medical use, lessons from cannabis are vital. Effective Public relations must challenge industry hype and promote rigorous Chemical synthesis and alkaloids research. Coordinated government regulation is essential for responsible Legalization, preventing undue for-profit influence and managing Recreation within this diverse academic research theme.
Abstract
Abstract The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, ac...
Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
American journal of therapeutics
Summary
Psychedelic medicines are reemerging as powerful tools for mental health treatment, with breakthrough results in treating depression, anxiety, and PTSD. Recent clinical trials show promising outcomes, particularly with MDMA for PTSD and psilocybin for depression. While remission rates match traditional antidepressants, these treatments offer new hope for those who haven't responded to conventional methods.
Abstract
Psychedelic drugs have recently emerged as plausibly effective pharmacological agents for the management of depression, anxiety, and other neuropsy...
Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review.
The primary care companion for CNS disorders – January 16, 2024
Summary
Regular microdosing of psychedelics like LSD and psilocybin shows promise for mental wellness, with users reporting improved mood and focus. Analysis of multiple studies reveals consistent benefits for daily functioning, though some participants experienced mild discomfort. Positive expectations often aligned with better outcomes in controlled trials.
Abstract
Objective: To investigate the relationship between psychedelic microdosing and its effects on mental health, aiming to understand if microdosing ca...
Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation.
Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees – June 27, 2023
Summary
Emerging research reveals that psychedelics' therapeutic benefits may be deeply linked to their consciousness-altering effects. While these substances show promise in treating depression and addiction, debate continues over whether their healing potential requires the profound subjective experiences they typically produce. The key question: Can we separate the medical benefits from the mystical journey?
Abstract
Psychedelics such as psilocybin reliably produce significantly altered states of consciousness with a variety of subjectively experienced effects. ...
Contribution of serotonin 5-HT<sub>2A</sub> receptor to antidepressant effect of serotonergic psychedelics
Folia Pharmacologica Japonica – March 28, 2023
Summary
A compelling finding in Medicine reveals that 30-40% of major depressive disorder patients are treatment-resistant. While Ketamine offers an antidepressant option, Psilocybin, a Serotonergic hallucinogen alkaloid, is emerging as a safer alternative. Recognized by the FDA as a "breakthrough therapy," Psilocybin shows fast, lasting effects, even for treatment-resistant cases. This "psychedelic renaissance" in Psychiatry explores how these compounds, including Lysergic acid diethylamide, influence Serotonin receptors. Psychology and Pharmacology are delving into their mechanisms, offering hope for Anxiety and depression via Neurotransmitter Receptor Influence on Behavior, advancing Psychedelics and Drug Studies.
Abstract
Major depressive disorder presents a substantial global health burden, and at least 30-40% of patients exhibit treatment resistance to antidepressa...
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Journal of clinical psychopharmacology
Summary
Recent clinical trials reveal promising results for psychedelic compounds in treating depression, with psilocybin, LSD, and ayahuasca showing rapid mood improvements. Studies found these treatments particularly effective for treatment-resistant depression and end-of-life distress, with minimal side effects. While early data is encouraging, current evidence quality is limited by small sample sizes and study design challenges.
Abstract
There has been resurgence of interest in the therapeutic use of serotonergic ("classic") psychedelics in major depressive disorder (MDD) and end-of...
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv Preprint Archive – November 29, 2024
Summary
Psychedelics like LSD and psilocybin can rewire brain connections after just one dose, unlike traditional psychiatric medications. These compounds boost the brain's natural plasticity, helping neurons form new pathways and adapt to change. Studies show they create a window of enhanced learning and adaptation, leading to lasting improvements in mood and behavior.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials.
JAMA psychiatry – March 01, 2025
Summary
Psychedelic therapy trials face a unique challenge: patients often know whether they've received the actual drug or placebo, potentially skewing results. Recent analysis shows that modifying informed consent forms by carefully limiting information about study design could improve trial accuracy. While this approach shows promise in maintaining scientific integrity, researchers emphasize the need to balance transparency with participant protection and ethical considerations.
Abstract
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination ...
Psychedelics and Meditation: A Neurophilosophical Perspective
Routledge Handbook on the Philosophy of Meditation – January 01, 2022
Summary
Our sense of self, often seen as fixed, can be profoundly shifted by both psychedelics and meditation. A neurophilosophical perspective reveals deep commonalities. Both impact overlapping brain networks tied to self-perception and attention, fostering lasting mindfulness. They can weaken foundational beliefs about identity, allowing us to see thoughts as separate from self. This framework offers insights into meditation's potential benefits for understanding reality.
Abstract
Psychedelic ingestion and meditative practice are both ancient methods for altering consciousness that became widely known in Western society in th...
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions
Frontiers in Psychology – July 25, 2017
Summary
A compelling finding in applied psychology reveals that music therapy significantly shapes mystical experiences during psilocybin sessions. Ten psychotherapists and staff, experienced in clinical psychology and Psychedelics and Drug Studies, identified 22 musical examples optimally supporting peak effects. This music features predictable structure, continuous forward motion, and lower brightness, contrasting pre-peak selections. This specific guidance for music selection aids future psychedelic research, enhancing therapeutic outcomes and understanding the cognitive psychology of altered states.
Abstract
Psilocybin is a classic (serotonergic) hallucinogen ("psychedelic" drug) that may occasion mystical experiences (characterized by a profound feelin...
Psychedelic Science of Spirituality and Religion: An Attachment-Informed Agenda Proposal
OpenAlex – December 25, 2021
Summary
Psychedelics hold profound potential to reshape our deepest relational patterns, offering a new perspective on spirituality. Integrating Attachment theory with Psychology, this framework suggests natural compounds might relax rigid beliefs formed by early interpersonal communication. Psychological intervention, often guided by a psychotherapist, could then foster increased attachment security. Phenomenology reveals these experiences, from a Social psychology perspective, alleviate attachment-related worries and promote connection to others and the divine. This agenda outlines how chemical synthesis of alkaloids in Psychedelics and Drug Studies could offer significant therapeutic benefits.
Abstract
In this paper, we set an agenda for a psychedelic science of spirituality and religion, based on a synthesis of attachment theory with the Relaxed ...
Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses
OpenAlex – June 10, 2021
Summary
Psychedelics like psilocybin show promising efficacy for psychiatric conditions, driving interest in their neurocognitive effects. Functional magnetic resonance imaging (fMRI) is a key neuroimaging tool, with 42 articles analyzing resting-state fMRI data from 17 unique datasets on drug effects. However, this field of Psychedelics and Drug Studies faces significant methodological heterogeneity. Nearly all studies vary in data processing, and over half the literature stems from just two datasets. To advance understanding of functional brain connectivity in neuroscience and psychology, greater consistency and replicability are crucial.
Abstract
Clinical research into serotonergic psychedelic drugs including psilocybin, LSD and N,N-DMT (e.g., in ‘ayahuasca’) is expanding rapidly and clinica...
4 Psychedelics: therapeutic mechanisms
Journal of Neurology Neurosurgery & Psychiatry – July 20, 2020
Summary
Psychedelics like Psilocybin are profoundly reshaping our understanding of mental health. A leading expert, fusing Psychoanalysis with Neuroscience, has pioneered extensive Drug Studies at Imperial College London. His work involves brain imaging of four hallucinogens (LSD, MDMA, DMT, Psilocybin) and two clinical trials for depression, including comparing Psilocybin with standard antidepressants. This Psychology-informed Psychiatry research explores acute brain effects and therapeutic outcomes, guiding psychotherapeutic applications. Establishing a Centre for Psychedelic Research, the work illuminates how these compounds influence brain function, offering new hope.
Abstract
Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA ...
Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative
Anthropology of Consciousness – August 22, 2022
Summary
Psychedelic medicines, long central to Indigenous and counterculture wisdoms, are now driving multimillion-dollar IPOs in Medicine and Psychiatry. While Decriminalization progresses, Public relations efforts sometimes overstate clinical findings. Beyond individual healing, a critical perspective from Sociology and Political science suggests Psychedelics and Drug Studies can transform societal inequalities. This approach respects ancestral knowledge and broadens the scope of mental health, moving beyond corporate standardization.
Abstract
Psychedelic or ecodelic medicines (e.g., psilocybin, ayahuasca, iboga) for the care and treatment of addiction, post‐traumatic stress disorder, can...
Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts
Drug Science Policy and Law – January 01, 2020
Summary
Individuals with low psychological well-being (643 respondents) were more likely to report positive mood changes after using psychedelics like lysergic acid diethylamide or psilocybin, and MDMA. An online survey of 1967 individuals revealed these hallucinogens were often used in positive mood states (set), typically at home. Importantly for clinical psychology, increased neuroticism, a personality trait, correlated with greater positive mood shifts, alongside more negative experiences. This highlights potential for psychiatry in Psychedelics and Drug Studies.
Abstract
Background It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the...
Should Adolescents be Included in Emerging Psychedelic Research?
Canadian Journal of Bioethics – January 01, 2022
Summary
Psychedelic substances like psilocybin show significant promise for adult mental health, yet adolescent inclusion in psychological intervention trials is currently 0%. A compelling argument highlights the urgent need for novel medical interventions to address growing youth mental health burdens. Psychedelics pose low risk compared to existing psychiatric medications. While developmental risks and informed consent complexities exist, including adolescents in clinical psychology and drug studies is crucial. This would improve their quality of life, offering innovative treatments and advancing diverse academic research themes in medicine and psychology.
Abstract
Recent evidence shows significant potential for therapies involving psychedelic substances such as psilocybin and MDMA to improve clinical outcomes...
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
British Journal of Pharmacology – September 02, 2025
Summary
High-dose psilocybin, a classic hallucinogen, uniquely boosts dopamine in the brain's nucleus accumbens, a region critical for addiction. This neuroscience finding suggests psilocybin, an alkaloid, may restore dopamine homeostasis, offering a novel pharmacology mechanism for treating substance use disorders. Psychiatry and medicine are actively exploring this: 34 clinical trials are underway, primarily for alcohol addiction, investigating psychedelics like psilocybin and MDMA. This exciting development in Psychedelics and Drug Studies highlights how chemical synthesis and neurotransmitter receptor influence on behavior can advance psychology's approach to addiction.
Abstract
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depre...
The frontiers of new psychedelic therapies: A survey of sociological themes and issues
Sociology Compass – February 01, 2022
Summary
Psychedelic therapies are poised to revolutionize mental health treatment for conditions like depression, anxiety, and PTSD. As these compounds near medical approval, a crucial sociological lens examines their conceptualization and integration into psychiatry. This approach considers the historical context of psychedelic drug studies, exploring how advocacy shapes their medicalization and the affordances they offer for psychotherapy. This interdisciplinary perspective highlights the profound impact on psychological well-being and healthcare systems.
Abstract
Abstract Psychedelic compounds are on the cusp of being approved by medical regulators for treatment‐resistant mental health disorders. Following p...
Psychedelics and psychiatric disorders: A emerging role
European Psychiatry – April 01, 2021
Summary
Psychedelics like Psilocybin, Lysergic acid diethylamide (LSD), and Mescaline, along with MDMA, demonstrate significant, enduring therapeutic potential in Psychiatry and Clinical Psychology. These hallucinogens offer immediate anti-depressant and anti-anxiety effects, proving effective for depression, cancer-related anxiety, PTSD, and addiction. In Medicine, Psychedelics and Drug Studies show these compounds, influencing behavior via neurotransmitter receptors, are well-tolerated. Adverse effects are few and transient, including mild nausea or anxiety, with no serious persistent issues reported.
Abstract
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), ps...
Not all serotonergic psychedelics are alike - they induce distinct patterns of altered metabolic activity and connectivity
OpenAlex – May 28, 2024
Summary
Psilocybin, a powerful hallucinogen, uniquely alters brain activity compared to LSD and 2C-B. Neuroscience on three psychedelics in rat brains showed psilocybin specifically rewired cortical regions, influencing behavior. Conversely, LSD and 2C-B similarly inhibited the anterior cingulate cortex and boosted dopamine-rich areas. These distinct pharmacological actions, influencing neurotransmitter receptors, are crucial for Medicine and Psychedelics and Drug Studies. Understanding these differences in brain activity can guide treatments for neuropsychiatric disorders, including anxiety, and inform future drug development.
Abstract
Serotonergic psychedelic drugs have shown promising benefits in trials for various neuropsychiatric disorders. While the acute effects of these psy...
Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire
Frontiers in Psychology – September 15, 2025
Summary
Vivid aesthetic experiences during psychedelic use can predict improvements in well-being. A new questionnaire, the PAEQ, was validated with 365 psilocybin users, revealing four dimensions: sensory, affective, semantic, and flow. The PAEQ demonstrated high reliability (α=0.90) and strong correlations with existing measures (e.g., r=0.69). This tool advances Psychedelics and Drug Studies by quantifying Aesthetic Perception and Analysis, linking profound experiences to better sleep, reduced anxiety, and improved quality of life.
Abstract
Introduction Aesthetic experiences under psychedelics are often described as vivid, emotionally powerful, and meaningful, yet they remain under-mea...
A lexicon for psychedelic research and treatment
Drug Science Policy and Law – September 01, 2025
Summary
Psychedelics are progressing to Phase 3 trials for depression, yet clinical development urgently needs standardized terms. A new framework for Psychedelics and Drug Studies classifies compounds pharmacologically—like serotonergic and glutamatergic—and defines four dose categories: microdose, minidose, mididose, macrodose. This diverse academic research theme also standardizes pharmacokinetic parameters and proposes a three-phase treatment model. Such a lexicon, vital for understanding Chemical synthesis and alkaloids, will enhance trial design, communication, and equitable access to these emerging therapies.
Abstract
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant ...
Race as a component of set and setting: How experiences of race can influence psychedelic experiences
Journal of Psychedelic Studies – September 19, 2019
Summary
Race profoundly shapes individual experiences with psychedelics. A conceptual review argues that psychosocial factors influencing racial differences in mental health create distinct psychological "set" for users. The character of US race relations provides a unique cultural "setting" for racialized individuals in both therapeutic and naturalistic contexts. This influences the framing and interpretation of experiences, impacting harm reduction. This social psychology analysis is crucial for developing clinical protocols for psychotherapists and ensuring cross-cultural mental health support in psychedelics and drug studies.
Abstract
Background and aims Set and setting function both as a concept that guides research and practice with psychedelic drugs and as a meme aimed at redu...
Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience
Journal of Psychedelic Studies – September 16, 2022
Summary
A review of 15 studies involving 2,182 participants reveals that psychedelic experiences promoting ego-dissolution and social connectedness significantly improve mental health. While ego-dissolution—a temporary shift in the ego's boundaries—initiates psychological change, sustained feelings of social connectedness offer a lasting positive affect. Clinical psychology can leverage these insights from Psychedelics and Drug Studies. Psychotherapists might emphasize ego-dissolution during preparation and foster social connectedness for integration, enhancing mental health outcomes and informing the broader narrative in social psychology.
Abstract
Abstract Background and aims Despite promising findings indicating the therapeutic potential of psychedelic experience across a variety of domains,...
Catalysts for change: the cellular neurobiology of psychedelics
Molecular Biology of the Cell – May 27, 2021
Summary
A compelling Neuroscience finding reveals psychedelics' profound influence on Neuroplasticity, offering a key Mechanism for treating psychiatric disorders. Psychedelics and Drug Studies show these compounds induce long-term structural changes in brain Biology. Intricate cellular and subcellular mechanisms, including specific Neurotransmitter Receptor Influence on Behavior, are illuminated by Biochemical Analysis and Sensing Techniques. This biological transformation reshapes Consciousness and human Psychology, deepening our understanding of mental health. Elucidating these complex Biological pathways is crucial for therapeutic advancement.
Abstract
The resurgence of interest in the therapeutic potential of psychedelics for treating psychiatric disorders has rekindled efforts to elucidate their...
Psychedelic Experiences and Mindfulness are Associated with Improved Wellbeing
OpenAlex – March 05, 2021
Summary
Personal mindfulness meditation practices and recreational psychedelic use are strongly linked to improved psychological wellbeing. A study of 1219 individuals engaging in both revealed that both mindfulness and mystical experiences substantially predict increased wellbeing. Importantly, psychedelics act as a key moderation factor, amplifying how mystical experiences contribute to wellbeing. This pioneering work in clinical and social psychology offers crucial insights into the naturalistic benefits of these practices, moving beyond traditional psychotherapist approaches and informing future drug studies and natural compound pharmacology.
Abstract
Both psychedelics and mindfulness are a recently emerging topic of interest in academia and popular culture alike. Personal meditation practices an...
Breaking through the doors of perception, consciousness, and existence: to what extent does psychedelic phenomenology ontologically depend on external factors?
Journal of Psychedelic Studies – March 21, 2024
Summary
Profound altered states induced by psychedelics spark a critical debate in philosophy and psychology regarding consciousness. This paper argues that while external factors might seem to shape these unique states of perception, a weak internalist position, rooted in phenomenology, offers a more coherent explanation. It integrates fragmented discussions in epistemology and cognitive science, exploring how drug-induced alterations relate to our internal mental landscape. Ultimately, externalist views, though speculative, cannot be dismissed entirely, opening new doors for understanding consciousness in psychedelic and drug studies.
Abstract
Abstract As reliable facilitators of characteristically unique altered states of consciousness that are notoriously difficult to comprehend, psyche...
Psychedelics and Mental Health Treatment Seeking Among Asians and Hawaiians
Psychoactives – September 04, 2025
Summary
For Native Hawaiians, psychedelic use is remarkably linked to *increased* mental health care access, contrasting with White individuals where it's associated with less formal treatment. Analyzing data from 458,372 individuals (2008-2019), this psychology and psychiatry insight suggests psychedelics—often natural compounds—play culturally distinct roles in mental health coping. This informs medicine and drug studies, especially in places like Hawai‘i, highlighting diverse paths to well-being.
Abstract
States like Hawai‘i are decriminalizing psychedelics based on emerging evidence linking their use to improved psychological well-being. Yet, in man...
Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment.
Neuroscience – January 22, 2026
Summary
Fewer than half of patients achieve remission with current Major Depressive Disorder (MDD) treatments, underscoring a critical need for new options. Classic psychedelics are emerging as a promising treatment. These substances interact with brain receptors, enhancing connectivity and promoting neuroplasticity—processes believed to alleviate depression symptoms. Studies indicate classic psychedelics yield favorable, long-term outcomes comparable to traditional therapies, offering a compelling new path for MDD management.
Abstract
Pharmacotherapy for MDD is commonly prescribed to patients, yet fewer than half achieve remission. Moreover, many patients exhibit intolerant respo...
The high frequency oscillation in orbitofrontal cortex is susceptible to phenethylamine psychedelic 25C-NBOMe in male rats.
Neuropharmacology – April 01, 2023
Summary
Psychedelics like 25C-NBOMe profoundly alter brain activity. A 0.1 mg/kg dose of 25C-NBOMe in rats boosted High frequency oscillation (120-150 Hz) specifically in the orbitofrontal Prefrontal cortex, peaking in 20-30 minutes. This increased activity strengthened Oscillatory coherence *within* prefrontal regions. These findings illuminate how psychedelics reorganize brain rhythms, potentially explaining their mind-altering effects and offering a biological marker for their impact.
Abstract
Serotoninergic psychedelics induced extensive alterations in perception and cognition, which has been attributable to its disruptive effect on osci...
Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.
Focus (American Psychiatric Publishing) – July 01, 2024
Summary
Psychedelic compounds like psilocybin show promise in treating anorexia nervosa by targeting serotonin pathways and improving cognitive flexibility. Research using animal models reveals that these substances may help break rigid eating patterns by activating specific brain receptors. Studies combining behavioral therapy with carefully monitored psychedelic medicine could offer new hope for this challenging condition.
Abstract
Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective d...
The effect of psychedelics on the level of brain-derived neurotrophic factor: A systematic review and meta-analysis.
Journal of psychopharmacology (Oxford, England) – May 01, 2024
Summary
Psychedelics like LSD, MDMA, and psilocybin may boost levels of BDNF, a key protein that helps brain cells grow and form new connections. Analysis of nine studies revealed that people who used psychedelics had significantly higher levels of brain-derived neurotrophic factor compared to those who didn't. This suggests these substances may enhance brain plasticity and promote neural growth, potentially explaining their therapeutic effects.
Abstract
Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways...
The Potential of Psychedelics for the Treatment of Episodic Migraine.
Current pain and headache reports – September 01, 2023
Summary
Promising breakthrough: A single low dose of psilocybin, the active compound in psychedelic mushrooms, reduced both migraine frequency and pain intensity for two weeks in patients with episodic headaches. The treatment showed both immediate relief and lasting benefits, offering hope for millions who suffer from debilitating migraines. The findings suggest psychedelics could revolutionize migraine care.
Abstract
This review presents the existing literature of and a framework for how psychedelic drugs might be applied as therapeutic agents in episodic migrai...
Confronting the figure of the "mad scientist" in psychedelic history: LSD's use as a correctional tool in the postwar period.
Frontiers in psychology – January 01, 2023
Summary
In postwar Canada, respected psychiatrists used LSD therapy in prisons, challenging our modern image of "mad scientists" conducting reckless experiments. Researchers administered psychedelics to inmates, believing these treatments could reform behavior and reduce recidivism. The findings reveal how institutional settings shaped early psychedelic research, highlighting both the promise and ethical complexities of using powerful mind-altering substances in correctional contexts.
Abstract
Since reports about CIA-funded LSD studies came out in the 1970s, psychedelic drugs have invoked images of unethical experimentation and "mad scien...
Molecular brain imaging of psychedelic action.
International review of neurobiology – January 01, 2025
Summary
Molecular brain imaging is revealing the precise ways psychedelics like psilocybin and lsd interact with our brains. Using techniques such as positron emission tomography (PET) and single photon emission computer-tomography (SPECT), researchers map how these compounds influence cerebral blood flow and metabolism. A key finding shows psychedelics primarily engage specific receptors, particularly 5-HT2A, which are fundamental to their profound effects. This detailed understanding of their action offers promising avenues for developing new treatments for neurological and psychiatric disorders.
Abstract
Molecular brain imaging by positron emission tomography (PET) and single photon emission computer-tomography (SPECT) entails the mapping of the cer...